Postoperative bridging with LMWH unnecessary in patients with AF: study

Post-procedure bridging with a low molecular weight heparin is not beneficial in patients with AF or mechanical heart valves who require temporary cessation of their warfarin. A Canadian study, published in The BMJ, comprised 1471 adults in whom warfarin was...

Post-procedure bridging with a low molecular weight heparin is not beneficial in patients with AF or mechanical heart valves who...

News in brief: Platelets activated in mild COVID-19; Inhibitor risk in haemophilia A: Deadly infections post-HCT

Platelets sensitive to SARS-CoV-2 exposure Platelet activation occurs in mild COVID-19 patients and in SARS-CoV-2 negative household contacts, according to Australian research. The results suggest that SARS-CoV-2-exposed individuals may have a SARS-CoV-2 infection below the detection threshold but sufficient for a platelet...

Platelets sensitive to SARS-CoV-2 exposure Platelet activation occurs in mild COVID-19 patients and in SARS-CoV-2 negative household contacts, according to Australian...

Blood cancers

Patients with chronic myeloid cancers may not be protected by COVID-19 vaccines

Haematologists in the UK have demonstrated impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Oxford University researchers measured anti-SARS-Cov2 IgG spike (S) antibody levels in 60 patients, more than two weeks following a single dose of either...

Haematologists in the UK have demonstrated impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Oxford University researchers...

Coagulation

Australian experience highlights advantages of emicizumab in infants with SHA, despite lack of data

The availability of emicizumab (Hemlibra) means that prophylaxis can now be offered for previously untreated infants with severe haemophilia A (SHA) without inhibitors, according to haematologists in Queensland. The monoclonal inhibitor product has been licensed for use in patients of all...

The availability of emicizumab (Hemlibra) means that prophylaxis can now be offered for previously untreated infants with severe haemophilia A...